TP53 and diffuse large B-cell lymphoma: Patients with chronic lymphocytic leukemia (CLL) who do not respond to targeted therapies have an unfavourable prognosis, particularly if tumor cells harbour high-risk genomic aberrations (e.g. TP53 aberrations or complex karyotype) or the disease has transformed into diffuse large B-cell lymphoma (DLBCL), also known as Richter’s transformation (RT) (1).